Top 10 Selling Cancer Drugs of 2024
- Keytruda - $29.5 billion
- Darzalex - $9 billion
- Opdivo - $7 billion
- Imbruvica - $5billion
- Tagrisso - $5 billion
- Revlimid - $4 billion
- Verzenio - $4 billion
- Imfinzi - $4 billion
- Ibrance - $3 billion
- Tecentriq - $3 billion
1. Keytruda (Pembrolizumab) - $29.5 billion
Indications Approved by FDA:- Non-small cell lung cancer (NSCLC)
- Melanoma
- Head and neck squamous cell carcinoma (HNSCC)
- Classical Hodgkin lymphoma
- Urothelial carcinoma
- Gastric cancer
- Esophageal cancer
- Triple-negative breast cancer (TNBC)
- Renal cell carcinoma (RCC)
- Microsatellite instability-high (MSI-H) cancers
- Colorectal cancer
- Hepatocellular carcinoma (HCC)
- Cervical cancer
Company: Merck & Co.
2023 sales: $25 billion
2023 sales: $25 billion
2024 sales: $29.5 billion
In 2024, Keytruda’s sales grew 18% at constant exchange rates, reaching $29.5 billion. After AbbVie's Humira lost U.S. market exclusivity and as demand for COVID vaccines plummeted at the end of the pandemic, Merck & Co.’s Keytruda was finally able to claim the title of the world’s bestselling medicine in 2023.
In 2024, Keytruda’s sales grew 18% at constant exchange rates, reaching $29.5 billion. After AbbVie's Humira lost U.S. market exclusivity and as demand for COVID vaccines plummeted at the end of the pandemic, Merck & Co.’s Keytruda was finally able to claim the title of the world’s bestselling medicine in 2023.
2. Darzalex (Daratumumab) - $11.6 billion
Indication Approved by FDA: Multiple myeloma and light chain amyloidosis.Mechanism of Action: Darzalex is a monoclonal antibody that targets CD38, a glycoprotein expressed on the surface of multiple myeloma cells. By binding to CD38, Darzalex induces tumor cell death through multiple mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis. It also modulates the immune system to attack the cancer cells.
Company: Johnson & Johnson
2023 sales: $9.7 billion
2023 sales: $9.7 billion
2024 sales: $11.6 billion
Darzalex secured its initial FDA approval in 2015 as a fourth-line multiple myeloma treatment and the first monoclonal antibody for the blood cancer. It entered the first-line setting in 2018 as part of a now outdated combination including Takeda’s Velcade, the alkylating agent melphalan and the corticosteroid prednisone.
Much more recently, the J&J drug has shown promise as part of an advanced combo with Velcade, Bristol Myers Squibb’s Revlimid and the steroid dexamethasone (VRd). Late last year, the Darzalex-containing four-drug regimen showed it could slash the risk of progression or death by 58% versus VRd alone in first-line myeloma patients who’re eligible for stem cell transplants. The company filed that combo with the FDA in January and secured a priority review.
3. Opdivo (Nivolumab) - $7 billion
Indications Approved by FDA:- NSCLC
- Melanoma
- RCC
- HNSCC
- Urothelial carcinoma
- Classical Hodgkin lymphoma
- Hepatocellular carcinoma
- Esophageal squamous cell carcinoma
- Gastric cancer
- Colorectal cancer with MSI-H/dMMR
- Small cell lung cancer (SCLC)
Companies: Bristol Myers Squibb and Ono Pharmaceutical
2023 sales: $10 billion
2023 sales: $10 billion
2024 sales: $9.3 billion
Bristol Myers Squibb (BMY) and Ono Pharmaceutical’s Opdivo, a treatment for melanoma and other cancers, generated $9.3 billion in global sales. In 2024, the melanoma-fighting medication alone accounted for nearly 20% of the company’s $48.3 billion in annual revenue.
4. Tagrisso (Osimertinib) - $5 billion
Indications Approved by FDA:- EGFR T790M mutation-positive NSCLC
- First-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations
5. Revlimid (Lenalidomide) - $5 billion
Indications Approved by FDA:- Multiple myeloma
- Mantle cell lymphoma
- Myelodysplastic syndromes (MDS)
- Follicular lymphoma
6. Verzenio (Abemaciclib) - $4 billion
Indications Approved by FDA: HR-positive, HER2-negative advanced or metastatic breast cancerMechanism of Action: Verzenio is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting CDK4/6, Verzenio prevents the phosphorylation of the retinoblastoma protein (Rb), leading to cell cycle arrest at the G1 phase, thereby inhibiting the proliferation of cancer cells.
7. Imfinzi (Durvalumab) - $4 billion
Indications Approved by FDA:- Unresectable stage III NSCLC
- Extensive-stage small cell lung cancer (ES-SCLC)
- Urothelial carcinoma
8. Ibrance (Palbociclib) - $4 billion
Indications Approved by FDA: HR-positive, HER2-negative advanced or metastatic breast cancerMechanism of Action: Ibrance is an oral CDK4/6 inhibitor, similar to Verzenio. It works by inhibiting CDK4/6, which leads to cell cycle arrest in the G1 phase. This action reduces cancer cell proliferation, particularly in HR-positive breast cancer.
9. Perjeta (Pertuzumab) - $3 billion
Indications Approved by FDA: HER2-positive breast cancerMechanism of Action: Perjeta is a monoclonal antibody that targets the HER2 receptor, a protein that is overexpressed in some breast cancers. Perjeta binds to a different epitope on HER2 than Herceptin (trastuzumab), allowing for a more comprehensive blockade of HER2 signaling. This dual inhibition results in a more potent suppression of tumor growth.
10. Tecentriq (Atezolizumab) - $3 billion
Indications Approved by FDA:
- NSCLC
- SCLC
- Urothelial carcinoma
- Triple-negative breast cancer (TNBC)
- Hepatocellular carcinoma (HCC)
Comments
Post a Comment